CGTLive®’s Weekly Rewind – May 2, 2025
Review top news and interview highlights from the week ending May 2, 2025.
Welcome to CGTLive®’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
1. FDA Approves Abeona Therapeutics' Epidermolysis Bullosa Gene Therapy Pz-Cel
The agency's decision was based on data from the phase 3 VIITAL study (NCT04227106).
2. Cassandra Gorsuch, PhD, on the Durability and Next Steps for the ARCUS Gene Editing Platform in DMD
The chief scientific officer at Precision Biosciences discussed the durable potential of ARCUS gene editing and the company’s next steps toward in-human trials for Duchenne muscular dystrophy.
3. The Evolving Landscape of Gene and Cell Therapies in Parkinson Disease: Pipeline Highlights
Emerging gene and cell therapies aim to slow Parkinson disease progression. Explore clinical updates on seven promising candidates in development.
4. Linda Marbán, PhD, on the Future of Capricor’s Cardiomyopathy Cell Therapy Deramiocel
The CEO of Capricor Therapeutics discussed future plans for the product after the promising data presented at MDA’s 2025 conference.
5. Exploring New Pathways in Muscular Dystrophy Research: From Fibrosis to Function
Matthew Alexander, PhD, a neuromuscular expert, discussed the evolving landscape of targeted therapies in muscular dystrophies, from fibrosis and glycosylation to combination strategies with gene therapy.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Related Articles
- Around the Helix: Cell and Gene Therapy Company Updates – September 17, 2025
September 17th 2025
- ImmunoLogic, Episode 6: "The Future of Personalized Cancer Vaccines”
September 15th 2025
- Top News in Lymphoma Cell Therapy for World Lymphoma Awareness Day 2025
September 15th 2025